(Q33343707)

26 July 2017

title

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma (English)

1 reference

26 July 2017

Rummel MJ

1

1 reference

26 July 2017

Chow KU

2

1 reference

26 July 2017

Karakas T

3

1 reference

26 July 2017

Jäger E

4

1 reference

26 July 2017

Mezger J

5

1 reference

26 July 2017

von Grünhagen U

6

1 reference

26 July 2017

Schalk KP

7

1 reference

26 July 2017

Burkhard O

8

1 reference

26 July 2017

Hansmann ML

9

1 reference

26 July 2017

Ritzel H

10

1 reference

26 July 2017

Bergmann L

11

1 reference

26 July 2017

Hoelzer D

12

1 reference

26 July 2017

Mitrou PS

13

1 reference

26 July 2017

publication date

1 September 2002

1 reference

European Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

38

1 reference

26 July 2017

issue

13

1 reference

26 July 2017

page(s)

1739-1746

1 reference

Which treatment for mantle-cell lymphoma patients in 1998?

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Cladribine for untreated or early low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

High activity of mitoxantrone in previously untreated low-grade lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900143-0

7 January 2021

10.1016/S0959-8049(02)00143-0

Identifiers

DOI

1 reference

26 July 2017

1 reference